Jim Cramer Says “LENZ Therapeutics Has a Promising Story”

Group 1 - LENZ Therapeutics, Inc. is focused on developing therapies for vision improvement, specifically through its eyedrop product, VIZZ [1][2] - The total addressable market for LENZ's product is estimated at 128 million people, indicating significant potential for patient uptake [1] - The company's stock has increased nearly 150% from its lows in April, suggesting strong market interest and momentum [1] Group 2 - Despite the potential of LENZ, there are opinions that certain AI stocks may offer greater upside potential with less downside risk [2] - The market capitalization of LENZ is currently at $1.19 billion, which may not fully reflect the scale of the opportunity available [1]